Nancy M. Hardy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nancy M. Hardy has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Jean A. Yared
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
3 shared publications Aaron P Rapoport
Department of Medicine, University of Maryland School of Medicine , Baltimore, Maryland
2 shared publicationsDjordje Atanackovic
Department of Medicine, University of Maryland School of Medicine , Baltimore, Maryland
2 shared publicationsAaron P. Rapoport
Transplantation & Cellular Therapy Program, Division of Hematology/Oncology, Department of Internal Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, University of Maryland School of Medicine, Baltimore, MD
1 shared publicationAbdulaziz Abu-Haimed
Department of Medicine, University of Maryland School of Medicine , Baltimore, Maryland
1 shared publicationAlan Howard
Center for International Blood and Marrow Transplant Research/National Marrow Donor Program, Minneapolis, MN
1 shared publication
Latest Publications
- Open Access
- 12 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1)
Beyond the typical immune effector cell-associated neurotoxicity syndrome: Characterizing non-immune effector cell-associated neurotoxicity syndrome neurological complications in chimeric antigen receptor T-cell therapy—A retrospective analysis
Background: Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed/refractory hematologic malignancies. While immune effector cell-associated neurotoxicity syndrome (ICANS) is a well-recognized complication, expanding clinical use has revealed distinct non-ICANS neurological complications that challenge standard diagnostic and management approaches. We characterize the clinical features and outcomes of these non-classic presentations. Methods: A retrospective analysis was conducted on 357 patients receiving commercial CAR-T therapy for non-Hodgkin lymphoma or multiple myeloma at a single academic center (2015-2025). Non-ICANS neurological complications were defined by neurologic deficits, movement disorders, or neurocognitive syndromes occurring in the absence of global encephalopathy (ICE scores 9-10). Institutional protocol included baseline neurology evaluation and brain MRI. Results: Non-ICANS complications occurred in 17 patients (4.76%). Manifestations included focal neuropathies or myelopathy (n = 5), progressive leukoencephalopathy (n = 4), neuropsychiatric symptoms (n = 3), Parkinsonism (n = 2), and cranial nerve palsies (n = 4). Compared to the institutional median for classic ICANS (7 days), non-ICANS demonstrated a prolonged median duration of 14 days (range, 4-365+ days). Abnormal brain MRI findings were present in 5 of 15 (33.3%) cases with post-treatment brain MRI, manifesting commonly as T2/FLAIR hyperintensities in the white matter. Cerebrospinal fluid (CSF) immunomonitoring in a subset of cases (n = 2) revealed an enrichment of CAR T-cells compared to peripheral blood. Conclusions: Non-ICANS neurological complications represent a distinct clinical subset characterized by atypical findings, neuroimaging abnormalities, and/or protracted recovery. Increased clinical vigilance and tailored diagnostic approaches are essential to mitigate long-term morbidity, as standard screening tools fail to capture these focal neurotoxicities.
- 12 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1)
Open AccessBeyond the typical immune effector cell-associated neurotoxicity syndrome: Characterizing non-immune effector cell-associated neurotoxicity syndrome neurological complications in chimeric antigen receptor T-cell therapy—A retrospective analysis
Background: Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed/refractory hematologic malignancies. While immune effector cell-associated neurotoxicity syndrome (ICANS) is a well-recognized complication, expanding clinical use has revealed distinct non-ICANS neurological complications that challenge standard diagnostic and management approaches. We characterize the clinical features and outcomes of these non-classic presentations. Methods: A retrospective analysis was conducted on 357 patients receiving commercial CAR-T therapy for non-Hodgkin lymphoma or multiple myeloma at a single academic center (2015-2025). Non-ICANS neurological complications were defined by neurologic deficits, movement disorders, or neurocognitive syndromes occurring in the absence of global encephalopathy (ICE scores 9-10). Institutional protocol included baseline neurology evaluation and brain MRI. Results: Non-ICANS complications occurred in 17 patients (4.76%). Manifestations included focal neuropathies or myelopathy (n = 5), progressive leukoencephalopathy (n = 4), neuropsychiatric symptoms (n = 3), Parkinsonism (n = 2), and cranial nerve palsies (n = 4). Compared to the institutional median for classic ICANS (7 days), non-ICANS demonstrated a prolonged median duration of 14 days (range, 4-365+ days). Abnormal brain MRI findings were present in 5 of 15 (33.3%) cases with post-treatment brain MRI, manifesting commonly as T2/FLAIR hyperintensities in the white matter. Cerebrospinal fluid (CSF) immunomonitoring in a subset of cases (n = 2) revealed an enrichment of CAR T-cells compared to peripheral blood. Conclusions: Non-ICANS neurological complications represent a distinct clinical subset characterized by atypical findings, neuroimaging abnormalities, and/or protracted recovery. Increased clinical vigilance and tailored diagnostic approaches are essential to mitigate long-term morbidity, as standard screening tools fail to capture these focal neurotoxicities.
- 5 January 2025
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 25 (6) , 432-439
CD19 CAR-T With Axicabtagene Ciloleucel in R/R Large B-Cell Lymphoma With/Without Prior Autologous Stem Cell Transplant
- 5 January 2025
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 25 (6) , 432-439
CD19 CAR-T With Axicabtagene Ciloleucel in R/R Large B-Cell Lymphoma With/Without Prior Autologous Stem Cell Transplant
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
2717. Beware the bacteria: risk of bacterial infections persists more than 60 days post CAR-T
Immunosuppressive conditioning regimens for chimeric antigen receptor-modified T cells (CAR-T) and subsequent T cell dysfunction increase risk for infection. Prior studies of infection risk after CAR-T have found bacterial infections are most common in the first month, and viral infections are more frequently seen after 30 days. We evaluated longer-term infection outcomes, up to 180 days post CAR-T infusion. We performed a retrospective chart review of 144 patients who received CAR-T infusion at our institution between March 2018 and March 2022. We collected data on demographics, type and timing of infections, onset and treatment of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) or Cytokine Release Syndrome (CRS), and mortality up to 180 days after CAR-T infusion. We determined if ICANS, CRS, or treatment for either was associated with infections using Chi-square test. The mean age of patients in our cohort was 59 years. Most patients were male (65%), White (66%), and had not received a prior stem cell transplant (78%). Fifty-one (35%) patients had at least one infection during the study period (29% bacterial, 13% viral, 2% fungal). Mortality was 23% at 180 days. Most infections occurred within 60 days post CAR-T (Figure 1). Infections occurring between days 61 and 180 were mostly bacterial. In addition, ICANS ≥grade 3 and CRS ≥grade 2 occurred in 22 (15%) and 54 (38%) patients, respectively; both were significantly associated with bacterial infection (p< 0.05). Infections 180 days after CAR-T. *includes bacteremia, pneumonia, and skin and soft tissue infections. This cohort analyzed long-term infection outcomes post CAR-T. Most infections occurred early after CAR-T, within 60 days, and ICANS and CRS were associated with bacterial infection. We found that infections still persisted late after CAR-T, between Days 61 and 180, and were predominately bacterial, rather than viral or fungal. The low rates of fungal infection throughout the study period may be due to our institution’s fungal prophylaxis protocol. Future analyses will elucidate risk factors for infections in the late CAR-T period. David J. Riedel, MD, MPH , Gilead: Advisor/Consultant
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access2717. Beware the bacteria: risk of bacterial infections persists more than 60 days post CAR-T
Immunosuppressive conditioning regimens for chimeric antigen receptor-modified T cells (CAR-T) and subsequent T cell dysfunction increase risk for infection. Prior studies of infection risk after CAR-T have found bacterial infections are most common in the first month, and viral infections are more frequently seen after 30 days. We evaluated longer-term infection outcomes, up to 180 days post CAR-T infusion. We performed a retrospective chart review of 144 patients who received CAR-T infusion at our institution between March 2018 and March 2022. We collected data on demographics, type and timing of infections, onset and treatment of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) or Cytokine Release Syndrome (CRS), and mortality up to 180 days after CAR-T infusion. We determined if ICANS, CRS, or treatment for either was associated with infections using Chi-square test. The mean age of patients in our cohort was 59 years. Most patients were male (65%), White (66%), and had not received a prior stem cell transplant (78%). Fifty-one (35%) patients had at least one infection during the study period (29% bacterial, 13% viral, 2% fungal). Mortality was 23% at 180 days. Most infections occurred within 60 days post CAR-T (Figure 1). Infections occurring between days 61 and 180 were mostly bacterial. In addition, ICANS ≥grade 3 and CRS ≥grade 2 occurred in 22 (15%) and 54 (38%) patients, respectively; both were significantly associated with bacterial infection (p< 0.05). Infections 180 days after CAR-T. *includes bacteremia, pneumonia, and skin and soft tissue infections. This cohort analyzed long-term infection outcomes post CAR-T. Most infections occurred early after CAR-T, within 60 days, and ICANS and CRS were associated with bacterial infection. We found that infections still persisted late after CAR-T, between Days 61 and 180, and were predominately bacterial, rather than viral or fungal. The low rates of fungal infection throughout the study period may be due to our institution’s fungal prophylaxis protocol. Future analyses will elucidate risk factors for infections in the late CAR-T period. David J. Riedel, MD, MPH , Gilead: Advisor/Consultant
- Top Cited Papers
- 20 June 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (18) , 1971-1982
National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide
PURPOSE: Hematopoietic cell transplantation (HCT) is curative for hematologic disorders, but outcomes are historically inferior when using HLA-mismatched donors. Despite unrelated donor registries listing > 38 million volunteers, 25%-80% of US patients lack an HLA-matched unrelated donor, with significant disparity across ethnic groups. We hypothesized that HCT with a mismatched unrelated donor (MMUD) using post-transplant cyclophosphamide (PTCy), a novel strategy successful in overcoming genetic disparity using mismatched related donors, would be feasible and increase access to HCT.PATIENTS AND METHODS: We performed a prospective phase II study of MMUD bone marrow HCT with PTCy for patients with hematologic malignancies. The primary end point was 1-year overall survival (OS), hypothesized to be 65% or better. 80 patients enrolled at 11 US transplant centers (December 2016-March 2019). Following myeloablative or reduced-intensity conditioning–based HCT, patients received PTCy on days +3, +4, with sirolimus and mycophenolate mofetil starting on day +5. We compared outcomes to Center for International Blood and Marrow Transplant Research contemporary controls receiving PTCy.RESULTS: Notably, 48% of patients enrolled were ethnic minorities. 39% of pairs were matched for 4-6 out of 8 HLA alleles. The primary end point was met, with 1-year OS of 76% (90% CI, 67.3 to 83.3) in the entire cohort, and 72% and 79% in the myeloablative and reduced-intensity conditioning strata, respectively. Secondary end points related to engraftment and graft-versus-host-disease were reached. Multivariate analysis comparing the study group with other mismatched HCT controls found no significant differences in OS.CONCLUSION: Our prospective study demonstrates the feasibility and effectiveness of HCT with an MMUD in the setting of PTCy. Remarkably, nearly half of the study participants belonged to an ethnic minority population, suggesting this approach may significantly expand access to HCT.
- 20 June 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (18) , 1971-1982
Top Cited PapersNational Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide
PURPOSE: Hematopoietic cell transplantation (HCT) is curative for hematologic disorders, but outcomes are historically inferior when using HLA-mismatched donors. Despite unrelated donor registries listing > 38 million volunteers, 25%-80% of US patients lack an HLA-matched unrelated donor, with significant disparity across ethnic groups. We hypothesized that HCT with a mismatched unrelated donor (MMUD) using post-transplant cyclophosphamide (PTCy), a novel strategy successful in overcoming genetic disparity using mismatched related donors, would be feasible and increase access to HCT.PATIENTS AND METHODS: We performed a prospective phase II study of MMUD bone marrow HCT with PTCy for patients with hematologic malignancies. The primary end point was 1-year overall survival (OS), hypothesized to be 65% or better. 80 patients enrolled at 11 US transplant centers (December 2016-March 2019). Following myeloablative or reduced-intensity conditioning–based HCT, patients received PTCy on days +3, +4, with sirolimus and mycophenolate mofetil starting on day +5. We compared outcomes to Center for International Blood and Marrow Transplant Research contemporary controls receiving PTCy.RESULTS: Notably, 48% of patients enrolled were ethnic minorities. 39% of pairs were matched for 4-6 out of 8 HLA alleles. The primary end point was met, with 1-year OS of 76% (90% CI, 67.3 to 83.3) in the entire cohort, and 72% and 79% in the myeloablative and reduced-intensity conditioning strata, respectively. Secondary end points related to engraftment and graft-versus-host-disease were reached. Multivariate analysis comparing the study group with other mismatched HCT controls found no significant differences in OS.CONCLUSION: Our prospective study demonstrates the feasibility and effectiveness of HCT with an MMUD in the setting of PTCy. Remarkably, nearly half of the study participants belonged to an ethnic minority population, suggesting this approach may significantly expand access to HCT.
- 5 August 2020
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 23 (1) , 112-121
Immune effector cell–associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes
Background: CD19-directed chimeric antigen receptor (CAR) T-cell therapy (CAR-T) has emerged as effective for relapsed/refractory large B-cell lymphoma (R/R LBCL). The neurologic toxicity seen with CAR-T, referred to as immune effector cell–associated neurotoxicity syndrome (ICANS), is poorly understood. To better elucidate the clinical characteristics, treatment outcomes, and correlative biomarkers of ICANS, we review here a single-center analysis of ICANS after CAR T-cell therapy in R/R LBCL.Methods: Patients (n = 45) with R/R LBCL treated with axicabtagene ciloleucel (axi-cel) were identified. Data regarding treatment course, clinical outcomes, and correlative studies were collected. Patients were monitored and graded for ICANS via CARTOX-10 scoring and Common Terminology Criteria for Adverse Events (CTCAE) v4.03 criteria, respectively.Results: Twenty-five (56%) patients developed ICANS, 18 (72%) of whom had severe (CTCAE grades 3–4) ICANS. Median time to development of ICANS was 5 days (range, 3–11). Elevated pre-infusion (day 0 [D0]) fibrinogen (517 vs 403 mg/dL, upper limit of normal [ULN] 438 mg/dL, P = 0.01) and D0 lactate dehydrogenase (618 vs 506 units/L, ULN 618 units/L, P = 0.04) were associated with ICANS. A larger drop in fibrinogen was associated with ICANS (393 vs 200, P < 0.01). Development of ICANS of any grade had no effect on complete remission (CR), progression-free survival (PFS), or overall survival (OS). Duration and total dose of steroid treatment administered for ICANS did not influence CR, PFS, or OS.Conclusions: ICANS after CAR-T with axi-cel for R/R LBCL was seen in about half of patients, the majority of which were high grade. Contrary to previous reports, neither development of ICANS nor its treatment were associated with inferior CR, PFS, or OS. The novel finding of high D0 fibrinogen level can identify patients at higher risk for ICANS.
- 5 August 2020
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 23 (1) , 112-121
Immune effector cell–associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes
Background: CD19-directed chimeric antigen receptor (CAR) T-cell therapy (CAR-T) has emerged as effective for relapsed/refractory large B-cell lymphoma (R/R LBCL). The neurologic toxicity seen with CAR-T, referred to as immune effector cell–associated neurotoxicity syndrome (ICANS), is poorly understood. To better elucidate the clinical characteristics, treatment outcomes, and correlative biomarkers of ICANS, we review here a single-center analysis of ICANS after CAR T-cell therapy in R/R LBCL.Methods: Patients (n = 45) with R/R LBCL treated with axicabtagene ciloleucel (axi-cel) were identified. Data regarding treatment course, clinical outcomes, and correlative studies were collected. Patients were monitored and graded for ICANS via CARTOX-10 scoring and Common Terminology Criteria for Adverse Events (CTCAE) v4.03 criteria, respectively.Results: Twenty-five (56%) patients developed ICANS, 18 (72%) of whom had severe (CTCAE grades 3–4) ICANS. Median time to development of ICANS was 5 days (range, 3–11). Elevated pre-infusion (day 0 [D0]) fibrinogen (517 vs 403 mg/dL, upper limit of normal [ULN] 438 mg/dL, P = 0.01) and D0 lactate dehydrogenase (618 vs 506 units/L, ULN 618 units/L, P = 0.04) were associated with ICANS. A larger drop in fibrinogen was associated with ICANS (393 vs 200, P < 0.01). Development of ICANS of any grade had no effect on complete remission (CR), progression-free survival (PFS), or overall survival (OS). Duration and total dose of steroid treatment administered for ICANS did not influence CR, PFS, or OS.Conclusions: ICANS after CAR-T with axi-cel for R/R LBCL was seen in about half of patients, the majority of which were high grade. Contrary to previous reports, neither development of ICANS nor its treatment were associated with inferior CR, PFS, or OS. The novel finding of high D0 fibrinogen level can identify patients at higher risk for ICANS.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , TPS3096
Two phase I/II open label clinical trials evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 or MAGE-A10 in subjects with stage IIIb or stage IV non-small cell lung cancer (NCT02588612/NCT02592577).
TPS3096 Background: Non-small cell lung cancer (NSCLC) accounts for 84% of lung cancer. Survival has recently been impacted by molecularly targeted therapies and checkpoint inhibitors (CPI), and the promising CPI results implicate a role for the immune system in NSCLC. 10-40% of NSCLC express NY-ESO-1 or MAGE-A10 cancer/testis antigens. These studies will evaluate the safety and antitumor activity of genetically engineered affinity enhanced TCRs (NY-ESO-1c259T or MAGE-A10c796T) directed towards a NYESO-1 or MAGE-A10 derived peptides complexed with HLA-A*02. In addition, correlative studies to evaluate persistence, phenotype, functionality of engineered T cells, mechanisms of resistance and antigen spreading will be performed. Methods: Patients (pt) are screened (NCT02636855) to identify those who have the relevant HLA-A*02 alleles and NY-ESO-1 or MAGE-A10 tumor expression. For entry into either treatment protocol, pt must have Stage IIIb or IV NSCLC, have failed at least one platinum-containing regimen (may have received CPIs), have measurable disease, ECOG 0-1, adequate organ function, and be without brain metastases, history of severe autoimmune disease or current uncontrolled illness. Following apheresis, T cells are isolated and expanded with CD3/CD28 beads, transduced with a lentiviral vector containing the NY-ESO-1c259T or MAGE-A10c795 TCR, and infused into the pt following lymphodepleting chemotherapy with fludarabine and cyclophosphamide. The NY-ESO-1c259T study is a 10 pt study utilizing a dose of 1-6 x 109 transduced T cells. The MAGE-A10c796T first-in-human study is a modified 3+3 design in up to 28 pt with escalating doses of 0.1, 1.0 and 1-6 x 109 transduced T cells, with staggered treatments to allow for safety review; dose escalation will be guided by the DLT observed and by safety review committee guidance. Response to treatment will be assessed by RECIST v1.1 at weeks 4, 8, 16, 24, every 3 months (for 2 yr) and every 6 months until disease progression. Clinical trial information: NCT02588612/NCT02592577.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , TPS3096
Two phase I/II open label clinical trials evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 or MAGE-A10 in subjects with stage IIIb or stage IV non-small cell lung cancer (NCT02588612/NCT02592577).
TPS3096 Background: Non-small cell lung cancer (NSCLC) accounts for 84% of lung cancer. Survival has recently been impacted by molecularly targeted therapies and checkpoint inhibitors (CPI), and the promising CPI results implicate a role for the immune system in NSCLC. 10-40% of NSCLC express NY-ESO-1 or MAGE-A10 cancer/testis antigens. These studies will evaluate the safety and antitumor activity of genetically engineered affinity enhanced TCRs (NY-ESO-1c259T or MAGE-A10c796T) directed towards a NYESO-1 or MAGE-A10 derived peptides complexed with HLA-A*02. In addition, correlative studies to evaluate persistence, phenotype, functionality of engineered T cells, mechanisms of resistance and antigen spreading will be performed. Methods: Patients (pt) are screened (NCT02636855) to identify those who have the relevant HLA-A*02 alleles and NY-ESO-1 or MAGE-A10 tumor expression. For entry into either treatment protocol, pt must have Stage IIIb or IV NSCLC, have failed at least one platinum-containing regimen (may have received CPIs), have measurable disease, ECOG 0-1, adequate organ function, and be without brain metastases, history of severe autoimmune disease or current uncontrolled illness. Following apheresis, T cells are isolated and expanded with CD3/CD28 beads, transduced with a lentiviral vector containing the NY-ESO-1c259T or MAGE-A10c795 TCR, and infused into the pt following lymphodepleting chemotherapy with fludarabine and cyclophosphamide. The NY-ESO-1c259T study is a 10 pt study utilizing a dose of 1-6 x 109 transduced T cells. The MAGE-A10c796T first-in-human study is a modified 3+3 design in up to 28 pt with escalating doses of 0.1, 1.0 and 1-6 x 109 transduced T cells, with staggered treatments to allow for safety review; dose escalation will be guided by the DLT observed and by safety review committee guidance. Response to treatment will be assessed by RECIST v1.1 at weeks 4, 8, 16, 24, every 3 months (for 2 yr) and every 6 months until disease progression. Clinical trial information: NCT02588612/NCT02592577.